On the HCPLive Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.
April 21st 2024
Contrary to previous research, findings point to similar decreases in weight and improvements in glucose homeostasis between time-restricted eating and usual eating pattern groups.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Cases and Conversations™: Evidence-Based Approaches to Management of CKD in Your Patients with T2DM
September 25, 2024
Register Now!
Oncology Briefings™: Coordinating the Long-Term Management of Patients With Multiple Myeloma Between Primary Care and Oncology Practices
View More
Advances In™: The Potential Role of Ultra-Long-Acting Basal Insulin Therapies in Type 2 Diabetes
View More
6th Annual Advanced Practice Collaborative
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Cases and Conversations™: Guideline Recommendations for the Use of Basal Insulin Therapy in Type 2 Diabetes
View More
Advances In™ Rare Genetic Forms of Obesity: Emerging Therapeutic Targets
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
(CME) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
(COPE) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Clinical Consultations™: Optimal Approaches to Recognizing and Treating ANCA-Associated Vasculitis
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Medical Crossfire®: Optimizing Care for Patients With Anemia and Chronic Kidney Disease
View More
Community Practice Connections™: Navigating a New Era of Food Allergy Management
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
SURMOUNT-1: Tirzepatide Provides Significant, Sustained Weight Loss in Obesity
June 4th 2022A month and a half after topline results were announced in April, full data from SURMOUNT-1 was presented at ADA 2022 and demonstrate tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.
SURMOUNT-1 Results Tout Tirzepatide's Weight Loss Benefits
April 28th 2022Tirzepatide met both coprimary endpoints in SURMOUNT-1, with use contributing to reductions in body weight of up to 22.5% during the 72-week trial and more than 60% of those receiving the 15 mg dose achieving body weight reductions of 20% or more.